Abstract

The American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) recognise that the introduction of effective new therapies that potentially affect a large number of patients presents both opportunities and challenges.

The introduction of an angiotensin receptor–neprilysin inhibitor (ARNI) (valsartan/sacubitril) and a sinoatrial node modulator (ivabradine), when applied judiciously, complements established pharmacological and device-based therapies and represents a milestone in the evolution of care for patients with heart failure (HF). Accordingly, the writing committees of the 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure and the 2016 ESC Guideline on the Diagnosis and Treatment of Acute and Chronic Heart Failure concurrently developed recommendations for the incorporation of these therapies into clinical practice.

Working independently, each writing committee surveyed the evidence, arrived at similar conclusions, and constructed similar, but not identical, recommendations. Given the concordance, the respective organisations simultaneously issued aligned recommendations on the use of these new treatments to minimise confusion and improve the care of patients with HF.